Artax Biopharma

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
Nck adaptor proteinSmall molecule
Psoriasis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 January 2025Topline resultAX-158Phase 2a (NCT05725057) results in psoriasis: well tolerated, biomarker effects with PASI 75 responses in line

Financial reports

No financial reports recorded.